Benzinga Research

Get Benzinga Pro
Data & APIs
Events
Premarket
Advertise

Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto

Free Benzinga Pro Trial

Calendars

Analyst Ratings Calendar

Conference Call Calendar

Dividend Calendar

Earnings Calendar

Economic Calendar

Guidance Calendar

Stock Split Calendar

Trade Ideas

Free Stock Reports

Trade Idea Feed

Analyst Ratings

Unusual Options Activity

Free Newsletter

Government Trades

Perfect Stock Portfolio

Easy Income Portfolio

Short Interest

Largest Increase

Largest Decrease

Calculators

Margin Calculator

Forex Profit Calculator

100x Options Profit Calculator

Screeners

Top Momentum Stocks

Top Quality Stocks

Top Value Stocks

Top Growth Stocks

Comments

Loading...

Numinus Wellness Stock News

NUMIFOTCQB

Logo brought to you by Benzinga Data

Perks Buy Compare Brokers

Perks Buy Compare Brokers

$0.0202

0.000201.00%

At close: -

$0.0192

-0.00100-4.95%

After Hours: Mar 24, 4:00 PM EDT

Numinus Wellness (NUMIF) Forecast

News

Earnings Numinus Wellness (NUMIF) Options Guidance Dividends Analyst Ratings Insider Trades Short Interest

Latest Numinus Wellness Stock News | OTC:NUMIF | Benzinga

Get the latest news on Numinus Wellness stock with updates on market trends, financials, and analysis from Benzinga. Stay informed on Numinus Wellness performance

Categories: All

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

Friday, November 15, 2024

Numinus Wellness Sells US Clinics, Partners With Stella For Tech-Driven Mental Health Solutions
Juan Spínelli - Nov 15, 2024, 6:48PM

Friday, September 13, 2024

MDMA Therapy For PTSD Faces FDA Delay: Are There Other Ways Forward?
Juan Spínelli - Sep 12, 2024, 8:28PM

Friday, July 12, 2024

Psychedelics Co. Numinus Narrows Loss In Q3, Reports QoQ Decrease In Revenue, Gross Profit
Jelena Martinovic - Jul 12, 2024, 2:39PM

Saturday, June 22, 2024

Psychedelics-Focused Numinus Plans To Leverage This AI Technology Via New Strategic Acquisition
Jelena Martinovic - Jun 22, 2024, 2:35PM

Monday, April 15, 2024

Numinus Wellness Q2 2024 Revenue Declines Amid Clinic Reshuffling And Expected Industry Trends
Lara Goldstein - Apr 15, 2024, 4:13PM

Tuesday, March 26, 2024

Two Top Biotechs Forge MDMA Supply Deals For An Expanding Research Field
Lara Goldstein - Mar 26, 2024, 3:35PM
Utah Hospitals Will Soon Provide Psilocybin And MDMA Therapy For Mental Health Conditions
Lara Goldstein - Mar 25, 2024, 8:26PM

Saturday, March 16, 2024

Psychedelics Headlines: Substitution Survey, Frank Herbert's Magic Mushrooms, Celestial Plans And News Review
Lara Goldstein - Mar 16, 2024, 9:58AM

Thursday, February 15, 2024

Psyched: Psychedelics & Sex, MDMA And Federal Approval, Canadians For End-Of-Life Care And More
Lara Goldstein - Feb 15, 2024, 8:36AM

Saturday, January 27, 2024

Psyched: Suggestibility And Psychedelics' Effects, EU's $7M Research Fund, Australia's Treatment Delivery, BZ Podcast And More
Lara Goldstein - Jan 27, 2024, 10:00AM

Thursday, January 18, 2024

Numinus Wellness Continues Tight Expense Management With Strategic Reviews Underway
Lara Goldstein - Jan 18, 2024, 10:00AM

Thursday, January 11, 2024

30 Psychedelics Executives, Scientists & Influencers To Watch In 2024 And Beyond
Lara Goldstein - Jan 10, 2024, 7:56PM

Tuesday, December 05, 2023

Psyched: Defense Dept.'s Ketamine Trial, Cybin's Psilocybin, Metabolic Disorders, Reform Update And More
Lara Goldstein - Dec 5, 2023, 10:12AM

Thursday, November 30, 2023

Numinus Reports Q4 & Full Year Fiscal 2023 Results, Including Greatly Reduced Cash Burn Rate
The Dales Report - Nov 30, 2023, 11:27AM

Friday, September 15, 2023

Psychedelics Researchers & Industry Leaders Weigh In On Groundbreaking PTSD Treatment News
Lara Goldstein - Sep 15, 2023, 5:14PM

Tuesday, September 12, 2023

Psychedelic Drugs Market Will Generate Over $12B In Next 12 Years, NY Consulting Firm Predicts
Lara Goldstein - Sep 12, 2023, 4:35PM

Tuesday, June 20, 2023

Psyched: $75M In Federal Funds, Gov. Polis Opens MAPS Event, CNN's Show, Dock Ellis' LSD Pitch & More
Lara Goldstein - Jun 20, 2023, 5:01PM
MDMA Deals: Optimi Supplies Numinus-MAPS Program & PharmAla Exports To Australian University
Lara Goldstein - Jun 20, 2023, 8:43AM

Friday, June 16, 2023

Numinus Partners With MAPS To Conduct Phase 1 MDMA Assisted Therapy Investigational Study
The Dales Report - Jun 16, 2023, 1:06PM

Monday, June 05, 2023

Numinus' Clinical Arm To Lead Enrollment Site For MindMed's Phase 2b LSD Study
Lara Goldstein - Jun 5, 2023, 4:27PM

Wednesday, May 31, 2023

Psyched: LSD Microdosing For Depression, DMT For Anxiety, MDMA Octopuses And More
Lara Goldstein - May 31, 2023, 11:59AM

Tuesday, May 30, 2023

Numinus' Clinical Site Joins Compass' Phase 3 Program On Psilocybin Therapy For TRD
Lara Goldstein - May 30, 2023, 4:05PM

Monday, April 24, 2023

Psyched: LSD For Major Depression, Canada's Psilocybin Macrodose Trial, Treatments For Multiple Sclerosis And More
Lara Goldstein - Apr 24, 2023, 3:57PM

Wednesday, April 19, 2023

Numinus Wellness CEO Payton Nyquvest On Q2 2023 Financial Results And Numinus Network
The Dales Report - Apr 19, 2023, 12:55PM

Monday, April 17, 2023

Psyched: Clinical-Grade MDMA, LSD For Depression, Partnerships For Delivering Psychedelic Therapies & More
Lara Goldstein - Apr 17, 2023, 4:14PM

Friday, April 14, 2023

Numinus Q2 2023: 581% Revenue Growth, 820% In Gross Profit And Strong Cash Position
Lara Goldstein - Apr 14, 2023, 2:58PM

Thursday, April 13, 2023

EXCLUSIVE: Infrastructure Built For Healing: 'Consolidation And Legitimacy Are Crucial For Psychedelic Industry Growth'
Joana Scopel - Apr 13, 2023, 7:22PM
Psychedelic Stock Gainers And Losers From April 13, 2023
Benzinga Insights - Apr 13, 2023, 5:30PM

Wednesday, April 12, 2023

Psychedelic Stock Gainers And Losers From April 12, 2023
Benzinga Insights - Apr 12, 2023, 5:30PM
Check Out The Canadian Company Building On Several Vertical Psychedelics Businesses
Lara Goldstein - Apr 12, 2023, 1:52PM
Numinus Unveils Licensing Model To Independent Practitioners To Expedite Clinic Growth
The Dales Report - Apr 12, 2023, 12:20PM

Tuesday, April 11, 2023

Psychedelic Stock Gainers And Losers From April 11, 2023
Benzinga Insights - Apr 11, 2023, 5:30PM

Monday, April 10, 2023

Psychedelic Stock Gainers And Losers From April 10, 2023
Benzinga Insights - Apr 10, 2023, 5:30PM

Friday, April 07, 2023

Psychedelic Stock Gainers And Losers From April 7, 2023
Benzinga Insights - Apr 7, 2023, 5:30PM

Thursday, April 06, 2023

Psychedelic Stock Gainers And Losers From April 6, 2023
Benzinga Insights - Apr 6, 2023, 5:30PM
This Psychiatrist Says Cannabis Is A Minor-League Psychedelic & Undervalued Investment Opportunity
Joana Scopel - Apr 6, 2023, 10:17AM

Wednesday, April 05, 2023

Psyched: Canada's Case For Psilocybin Access And Microdose Trial, US Reform Update, Battle With DEA & More
Lara Goldstein - Apr 5, 2023, 9:57AM

Monday, April 03, 2023

Seelos Therapeutics, ATAI Life Sciences Among Top Psychedelic Movers Of Today
Benzinga Insights - Apr 3, 2023, 5:30PM

Monday, March 27, 2023

Want To Become A Psychedelic-Assisted Therapist? This Company Offers A 'Pathway' Course
Lara Goldstein - Mar 27, 2023, 7:01PM

Wednesday, March 15, 2023

In-Clinic Ketamine Businesses Are Shutting Down All Across The US, A Rising Trend?
Lara Goldstein - Mar 15, 2023, 1:39PM

Monday, March 13, 2023

EXCLUSIVE: Bienstar Wellness Expands Ibogaine Treatment For Addiction To Curitiba, 3rd Brazilian City Covered By The Co.
Javier Hasse - Mar 13, 2023, 1:59PM

Thursday, March 09, 2023

Psychedelic Stock Gainers And Losers From March 9, 2023
Benzinga Insights - Mar 9, 2023, 4:30PM

Wednesday, March 08, 2023

Numinus Wellness, Seelos Therapeutics Among Top Psychedelic Movers Of Today
Benzinga Insights - Mar 8, 2023, 4:30PM
Will Canada Follow Australia And Approve Psychedelic Assisted Therapy? This CEO Believes It Will
The Dales Report - Mar 8, 2023, 10:52AM

Monday, March 06, 2023

Psychedelic Stock Gainers And Losers From March 6, 2023
Benzinga Insights - Mar 6, 2023, 4:30PM

Friday, March 03, 2023

Cybin, GH Research Among Top Psychedelic Movers Of Today
Benzinga Insights - Mar 3, 2023, 4:30PM

Thursday, March 02, 2023

Psychedelic Stock Gainers And Losers From March 2, 2023
Benzinga Insights - Mar 2, 2023, 4:30PM

Wednesday, March 01, 2023

Cybin, GH Research Among Top Psychedelic Movers Of Today
Benzinga Insights - Mar 1, 2023, 4:30PM

Tuesday, February 28, 2023

Psychedelic Stock Gainers And Losers From February 28, 2023
Benzinga Insights - Feb 28, 2023, 4:30PM

Connect With Us

About Benzinga

About Us
Careers
Advertise
Contact Us

Market Resources

Advanced Stock Screener Tools
Options Trading Chain Analysis
Comprehensive Earnings Calendar
Dividend Investor Calendar and Alerts
Economic Calendar and Market Events
IPO Calendar and New Listings
Market Outlook and Analysis
Wall Street Analyst Ratings and Targets

Trading Tools & Education

Benzinga Pro Trading Platform
Options Trading Strategies and News
Stock Market Trading Ideas and Analysis
Technical Analysis Charts and Indicators
Fundamental Analysis and Valuation
Day Trading Guides and Strategies
Live Investors Events
Pre market Stock Analysis and News
Cryptocurrency Market Analysis and News

Ring the Bell

A newsletter built for market enthusiasts by market enthusiasts. Top stories, top movers, and trade ideas delivered to your inbox every weekday before and after the market closes.

Terms & Conditions
Do Not Sell My Personal Data/Privacy Policy
Disclaimer
Service Status
Sitemap

© 2025 Benzinga | All Rights Reserved